Solventum (NYSE:SOLV) Posts Quarterly Earnings Results, Beats Expectations By $0.13 EPS

Solventum (NYSE:SOLV) announced its earnings results on Tuesday. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.35 by $0.13, FiscalAI reports. The firm had revenue of $2.01 billion for the quarter, compared to analysts’ expectations of $1.97 billion. Solventum had a net margin of 18.69% and a return on equity of 25.26%. The business’s revenue was down 3.0% compared to the same quarter last year. During the same period in the prior year, the company earned $1.34 EPS. Solventum updated its FY 2026 guidance to 6.600-6.600 EPS.

Here are the key takeaways from Solventum’s conference call:

• Q1 results beat plan and expectations with organic sales up 2.1% and EPS of $1.48 (11% YoY), driven by volume, mix and new product launches.
• Separation and operational progress is solid—75% of system applications migrated, the Asia ERP cutover completed, >50% of TSAs exited (targeting >90% by end‑2026)—and the $500 million Transform for the Future program underpins management’s target of 50–100 bps of margin expansion in 2026.
• Tariffs remain a material headwind, expected at $100–$120 million annually, and no tariff refunds have been recognized in results to date.
• Capital allocation is active: the board approved up to $1 billion in buybacks (Q1 repurchases ~923k shares for $67M) while Acera added ~$28M of sales, giving the company flexibility to pursue tuck‑in M&A and return capital to shareholders.
• Timing note for modelers: management expects >$100M of orders to be pulled into Q2 ahead of the U.S. ERP cutover (planned for Q3) and to reverse mostly in Q3, with no change to full‑year guidance but with quarter‑to‑quarter phasing effects.

Solventum Trading Up 1.3%

Shares of NYSE:SOLV traded up $0.88 during trading on Wednesday, reaching $69.92. 932,944 shares of the company were exchanged, compared to its average volume of 1,213,756. The firm has a market capitalization of $12.12 billion, a PE ratio of 7.88, a P/E/G ratio of 1.10 and a beta of 0.59. The business’s fifty day simple moving average is $67.91 and its 200-day simple moving average is $74.51. Solventum has a 12-month low of $62.38 and a 12-month high of $88.20. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.23 and a quick ratio of 0.89.

Insider Activity at Solventum

In related news, Director Amy Mcbride Wendell bought 1,475 shares of Solventum stock in a transaction dated Tuesday, March 10th. The shares were acquired at an average cost of $68.03 per share, with a total value of $100,344.25. Following the completion of the transaction, the director owned 5,039 shares in the company, valued at $342,803.17. The trade was a 41.39% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.24% of the company’s stock.

Hedge Funds Weigh In On Solventum

Institutional investors have recently modified their holdings of the stock. Dynamic Technology Lab Private Ltd purchased a new position in shares of Solventum during the fourth quarter worth approximately $238,000. Vident Advisory LLC purchased a new position in shares of Solventum during the fourth quarter worth approximately $210,000. Groupe la Francaise increased its position in shares of Solventum by 8,950.0% during the fourth quarter. Groupe la Francaise now owns 1,991 shares of the company’s stock worth $158,000 after acquiring an additional 1,969 shares during the period. Quadrant Capital Group LLC increased its position in shares of Solventum by 21.3% during the fourth quarter. Quadrant Capital Group LLC now owns 1,424 shares of the company’s stock worth $113,000 after acquiring an additional 250 shares during the period. Finally, Quarry LP purchased a new position in shares of Solventum during the fourth quarter worth approximately $103,000.

Key Headlines Impacting Solventum

Here are the key news stories impacting Solventum this week:

• Positive Sentiment: Q1 results beat expectations — SOLV reported $1.48 EPS vs. $1.35 consensus and revenue of $2.01B vs. $1.97B, showing better-than-expected profitability and margins. This is the primary catalyst for the rally. SOLV Tops Q1
• Positive Sentiment: Raised/firm guidance — management set FY2026 EPS at 6.600 (top of prior range), above consensus, and said organic sales and free cash flow targets remain intact — supports forward earnings visibility. Q1 Financial Results
• Positive Sentiment: Management commentary and call highlights point to margin momentum (wound care and sterilization demand cited) — suggests structural improvement in profitability beyond the quarter. Earnings Call Highlights
• Positive Sentiment: Technical upside — SOLV recently cleared both the 20‑day and 50‑day moving averages, a short-term bullish signal that can attract technical traders. 20-Day Breakout 50-Day Breakout
• Positive Sentiment: Buy-side support: BTIG reaffirmed a Buy with an $89 target — adds a sizable upside scenario for investors to consider. BTIG Reaffirmed
• Neutral Sentiment: Full call transcript and investor materials are available for deeper read — useful for modeling margins and guidance execution risk. Earnings Call Transcript
• Neutral Sentiment: Analyst consensus remains mixed / Hold on average — suggests market opinion is not uniformly bullish despite the beat. Consensus Recommendation
• Negative Sentiment: Wells Fargo cut its price target from $83 to $70 and set an “equal weight” rating — this downgrade introduces near-term resistance and could cap gains if other shops follow. Wells Fargo PT Cut

Analysts Set New Price Targets

A number of research firms recently weighed in on SOLV. Weiss Ratings reissued a “hold (c)” rating on shares of Solventum in a research report on Tuesday, January 27th. Wall Street Zen lowered shares of Solventum from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. KeyCorp increased their price objective on shares of Solventum from $92.00 to $93.00 and gave the stock an “overweight” rating in a research report on Wednesday. Rothschild & Co Redburn began coverage on shares of Solventum in a research report on Tuesday, March 24th. They issued a “sell” rating and a $60.00 price objective on the stock. Finally, UBS Group reissued a “neutral” rating and issued a $78.00 price objective on shares of Solventum in a research report on Wednesday. Seven analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $85.91.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.